Literature DB >> 31036294

Activating mutations of the gp130/JAK/STAT pathway in human diseases.

Juliane Lokau1, Christoph Garbers2.   

Abstract

Cytokines of the interleukin-6 (IL-6) family are involved in numerous physiological and pathophysiological processes. Dysregulated and increased activities of its members can be found in practically all human inflammatory diseases including cancer. All cytokines activate several intracellular signaling cascades, including the Jak/STAT, MAPK, PI3K, and Src/YAP signaling pathways. Additionally, several mutations in proteins involved in these signaling cascades have been identified in human patients, which render these proteins constitutively active and result in a hyperactivation of the signaling pathway. Interestingly, some of these mutations are associated with or even causative for distinct human diseases, making them interesting targets for therapy. This chapter describes the basic biology of the gp130/Jak/STAT pathway, summarizes what is known about the molecular mechanisms of the activating mutations, and gives an outlook how this knowledge can be exploited for targeted therapy in human diseases.
© 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Activation; Interleukin-6; Jak1; Jak2; STAT3; gp130

Mesh:

Substances:

Year:  2018        PMID: 31036294     DOI: 10.1016/bs.apcsb.2018.11.007

Source DB:  PubMed          Journal:  Adv Protein Chem Struct Biol        ISSN: 1876-1623            Impact factor:   3.507


  7 in total

1.  JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance.

Authors:  Hatem E Sabaawy; Bríd M Ryan; Hossein Khiabanian; Sharon R Pine
Journal:  Carcinogenesis       Date:  2021-12-31       Impact factor: 4.741

2.  Tofacitinib inhibits inflammatory cytokines from ulcerative colitis and healthy mucosal explants and is associated with pSTAT1/3 reduction in T-cells.

Authors:  Rhonda M Brand; Beverley A Moore; Ashley Zyhowski; Aaron Siegel; Shikhar Uttam; E Jeffrey Metter; Jarret Engstrom; Randall E Brand; Nabanita Biswas; David C Whitcomb; David G Binion; Marc Schwartz; Ian McGowan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-12-23       Impact factor: 4.052

Review 3.  Jak-Stat Signaling Induced by Interleukin-6 Family Cytokines in Hepatocellular Carcinoma.

Authors:  Juliane Lokau; Victor Schoeder; Johannes Haybaeck; Christoph Garbers
Journal:  Cancers (Basel)       Date:  2019-11-01       Impact factor: 6.639

4.  Joint Reconstituted Signaling of the IL-6 Receptor via Extracellular Vesicles.

Authors:  Philipp Arnold; Wiebke Lückstädt; Wenjia Li; Inga Boll; Juliane Lokau; Christoph Garbers; Ralph Lucius; Stefan Rose-John; Christoph Becker-Pauly
Journal:  Cells       Date:  2020-05-24       Impact factor: 6.600

5.  JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL).

Authors:  Chella Krishna Vadivel; Maria Gluud; Sara Torres-Rusillo; Lasse Boding; Andreas Willerslev-Olsen; Terkild B Buus; Tea Kirkegaard Nielsen; Jenny L Persson; Charlotte M Bonefeld; Carsten Geisler; Thorbjorn Krejsgaard; Anja T Fuglsang; Niels Odum; Anders Woetmann
Journal:  Cancers (Basel)       Date:  2021-01-14       Impact factor: 6.639

6.  Local anesthetics impair the growth and self-renewal of glioblastoma stem cells by inhibiting ZDHHC15-mediated GP130 palmitoylation.

Authors:  Xiaoqing Fan; Haoran Yang; Chenggang Zhao; Lizhu Hu; Delong Wang; Ruiting Wang; Zhiyou Fang; Xueran Chen
Journal:  Stem Cell Res Ther       Date:  2021-02-04       Impact factor: 6.832

Review 7.  JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies.

Authors:  Bilal Rah; Rafiq A Rather; Gh Rasool Bhat; Abdul Basit Baba; Ifra Mushtaq; Muzamil Farooq; Tahira Yousuf; Sadaf B Dar; Sabra Parveen; Rukhsana Hassan; Fozia Mohammad; Iqbal Qassim; Abida Bhat; Shazia Ali; Mahrukh Hamid Zargar; Dil Afroze
Journal:  Front Pharmacol       Date:  2022-03-24       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.